[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anterior-ischemic-optic-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anterior-ischemic-optic-neuropathy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100496811","optic-nerve-sheath-ultrasound-in-giant-cell-arteritis-100496811",false,"NCT05749094","Optic Nerve Sheath Ultrasound in Giant Cell Arteritis","The Sonographic Assessment of the Optic Nerve Sheath in Giant Cell Arteritis","SONIC-GCA","Our population of interest is patients referred from any settings for suspected, new-onset GCA.\n\nInclusion criteria:\n\nTo be included in SONIC-GCA, participants must meet all the following criteria:\n\n1. Age \\> 50 years.\n2. Referral to a GCA clinic for suspected, new-onset GCA.\n3. Ability to understand and willingness to sign an informed consent form.\n4. Willingness to comply with study visits and procedures.\n\nExclusion criteria:\n\nAn individual who meets any of these criteria will be excluded from SONIC-GCA:\n\n1. Referral for a suspected GCA relapse.\n2. Current use of systemic glucocorticoids, with the following duration at the baseline visit: ≥ 14 consecutive days of oral glucocorticoids in the previous 30 days, or ≥ 7 consecutive days of oral glucocorticoids if intravenous glucocorticoids were administered in the previous 30 days.\n3. Current use of any conventional or biologic immunosuppressive therapy.\n4. Known previous medical history of retinal diseases, optic nerve diseases, demyelinating diseases, normotensive hydrocephalus, intracranial tumors (benign or malignant), or any conditions associated with intracranial hypertension.\n5. Any condition that impairs the ability to perform optic nerve sheath ultrasound or fundoscopy.","ALL","50 Years","99 Years",{"count":21,"type":22},285,"ESTIMATED","OBSERVATIONAL","The Sonographic Assessment of the Optic Nerve Sheath in Giant Cell Arteritis (SONIC-GCA) study will evaluate the performance of the optic nerve sheath diameter (ONSD), measured via ultrasound, to diagnose and monitor GCA. SONIC-GCA builds upon our previous pilot studies and will answer the following questions:\n\n1. What is the performance of ONSD to identify patients with new-onset, active GCA?\n2. Is ONSD useful for monitoring GCA relapses during follow-up?\n3. What is the intra- and interobserver reliability of ONSD measurements?\n4. Does ONSD differ between patients with and without GCA-related retinal findings?",[26,27,28],"Giant Cell Arteritis","Anterior Ischemic Optic Neuropathy","Optic Neuropathy, Ischemic","RECRUITING","2025-08-02",{"date":32,"type":33},"2025-08-07","ACTUAL",{"date":35,"type":22},"2025-08",{"date":37,"type":22},"2029-03",{"name":39,"class":40},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","OTHER",6,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100554564","visual-involvement-in-giant-cell-arteritis-100554564","NCT06500728","Visual Involvement in Giant Cell Arteritis","Visu-GCA","Inclusion Criteria:\n\n* For GCA group:\n\n  * Patients older than 18 years with clinically suspected or confirmed gigantocellular arteritis.\n  * Newly found visual involvement with suspected or confirmed correlation with vasculitis.\n  * Ability to express valid consent to study enrolment.\n* For control group:\n\n  * Patients older than 18 years with the ability to express valid consent to study enrolment.\n  * Newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.\n\nExclusion Criteria:\n\n* Pre-existing ophthalmological pathologies that may modify best visual acuity and\u002For alter ophthalmological semeiotics.\n* Concomitant active viral, bacterial, fungal and parasitic infections, including active or latent tuberculosis treated for less than 4 weeks and HIV, hepatitis C virus (HCV)\n\n  \u002Fhepatitis B virus (HBV) infections, involving the eyes and orbital cavities.\n* Concomitant systemic inflammations not attributable to GCA (inflammatory diseases in treatment-free remission are not excluded).\n* Any other condition judged by the investigators to be a contraindication of eligibility","18 Years",{"count":51,"type":22},762,"This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries.\n\nThe primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.",[26,54,55,27,56,57,58,59,60],"Visual Impairment","Central Retinal Artery Occlusion","Paracentral Acute Middle Maculopathy","Posterior Ischemic Optic Neuropathy","Retinal Ischemia","Blindness","Visual Disorder",[26,62,63,64,65,66,67],"Visual impairment","Optical Coherence Tomography (OCT)","High resolution Optical Coherence Tomography (HR-OCT)","Angio-Optical Coherence Tomography (OCT-A)","Fluorescein angiography","Indocyanine green angiography","2024-07-08",{"date":70,"type":33},"2024-07-15",{"date":72,"type":33},"2024-06-27",{"date":74,"type":22},"2030-06",{"name":76,"class":40},"ASST Fatebenefratelli Sacco",1]